Purinergic Signalling in Parkinson’s Disease: A Multi-target System to Combat Neurodegeneration

Dehay B, Bourdenx M, Gorry P et al (2015) Targeting α-synuclein for treatment of Parkinson’s disease: mechanistic and therapeutic considerations. Lancet Neurol 14:855–866 Olanow CW, Kieburtz K, Odin P et al (2014) Continuous intrajejunal infusion of levodopa–carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 13:141–149 Braak H, Del Tredici K, Rüb U et al (2013) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211 Ghavami S, Shojaei S, Yeganeh B et al (2014) Autophagy and apoptosis dysfunction in neurodegenerative disorders. Prog Neurobiol 112:24–49 Osellame LD, Duchen MR (2013) Defective quality control mechanisms and accumulation of damaged mitochondria link Gaucher and Parkinson diseases. Autophagy 9:1633–1635 Tansey MG, Goldberg MS (2010) Neuroinflammation in Parkinson’s disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 37:510–518 Zhang G, Xia Y, Wan F et al (2018) New perspectives on roles of alpha-synuclein in Parkinson’s disease. Front Aging Neurosci 10:370 Tretter L, Sipos I, Adam-Vizi V (2004) Initiation of neuronal damage by complex I deficiency and oxidative stress in Parkinson’s disease. Neurochem Res 29:569–577 Tretter L, Adam-Vizi V (2004) Generation of reactive oxygen species in the reaction catalyzed by alpha-ketoglutarate dehydrogenase. J Neurosci 24:7771–7778 Adam-Vizi V, Tretter L (2013) The role of mitochondrial dehydrogenases in the generation of oxidative stress. Neurochem Int 62:757–763 Milusheva E, Sperlagh B, Shikova L et al (2003) Non-synaptic release of [3H]noradrenaline in response to oxidative stress combined with mitochondrial dysfunction in rat hippocampal slices. Neuroscience 120:771–781 Milusheva E, Baranyi M, Kittel Á et al (2005) Increased sensitivity of striatal dopamine release to H2O2 upon chronic rotenone treatment. Free Radic Biol Med 39:133–142 Baranyi M, Milusheva E, Vizi ES et al (2006) Chromatographic analysis of dopamine metabolism in a Parkinsonian model. J Chromatogr 1120:13–20 Milusheva E, Baranyi M, Kormos E et al (2010) The effect of antiparkinsonian drugs on oxidative stress induced pathological [3H]dopamine efflux after in vitro rotenone exposure in rat striatal slices. Neuropharmacology 58:816–825 Baranyi M, Porceddu PF, Gölöncsér F et al (2016) Novel (hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson’s disease. Mol Neurodegener 11:6 Birkmayer W, Hornykiewicz O (1962) The l-dihydroxyphenylalanine (l-DOPA) effect in Parkinson’s syndrome in man: on the pathogenesis and treatment of Parkinson akinesis. Arch Psychiatr Nervenkrankh Z Gesamte Neurol Psychiatr 203:560–574 Birkmayer W, Hornykiewicz O (1964) Additional experimental studies on l-DOPA in Parkinson’ syndrome and Reserpine Parkinsonism. Arch Psychiatr Nervenkrankh 206:367–381 Cotzias GC, Van Woert MH, Schiffer LM (1967) Aromatic amino acids and modification of Parkinsonism. N Engl J Med 276:374–379 Cotzias GC, Papavasiliou PS, Gellene R (1969) Modification of Parkinonism-chronic treatment with l-DOPA. N Engl J Med 280:337–345 Navarro G, Borroto-Escuela DO, Fuxe K et al (2016) Purinergic signaling in Parkinson’s disease. Relevance for treatment. Neuropharmacology 104:161–168 Lang AE (2009) When and how should treatment be started in Parkinson disease? Neurology 72:S39–S43 Olanow CW, Stern MB, Sethi K (2009) The scientific and clinical basis for the treatment of Parkinson disease. Neurology 72:S1–S136 Pinna A, Serra M, Morelli M et al (2018) Role of adenosine A2A receptors in motor control: relevance to Parkinson’s disease and dyskinesia. J Neural Transm (Vienna) 125:1273–1286 Burnstock G, Campbell G, Satchell D et al (1970) Evidence that adenosine triphosphate or a related nucleotide is the transmitter substance released by non-adrenergic inhibitory nerves in the gut. Br J Pharmacol 40:668–688 Burnstock G (1972) Purinergic nerves. Pharmacol Rev 24:509–581 Burnstock G (1976) Do some nerve cells release more than one transmitter? Neuroscience 1:239–248 Burnstock G (1997) The past, present and future of purine nucleotides as signaling molecules. Neuropharmacology 36:1127–1139 Burnstock G (2009) Purinergic cotransmission. Exp Physiol 94:20–24 Potter P, White TD (1980) Release of adenosine 5′-triphosphate from synaptosomes from different regions of rat brain. Neuroscience 5:1351–1356 Poelchen W, Sieler D, Wirkner K et al (2001) Co-transmitter function of ATP in central catecholaminergic neurons of the rat. Neuroscience 102:593–602 Sperlágh B, Sershen H, Lajtha A et al (1998) Co-release of endogenous ATP and [3H]noradrenaline from rat hypothalamic slices: origin and modulation by α2-adrenoreceptors. Neuroscience 82:511–520 Jo YH, Role LW (2002) Coordinate release of ATP and GABA at in vitro synapses of lateral hypothalamic neurons. J Neurosci 22:4794–4804 Mori M, Heuss C, Gahwiler BH et al (2001) Fast synaptic transmission mediated by P2X receptors in CA3 pyramidal cells of rat hippocampal slice cultures. J Physiol 535:115–123 Krügel U, Kittner H, Franke H et al (2003) Purinergic modulation of neuronal activity in the mesolimbic dopaminergic system in vivo. Synapse 47:134–142 Zimmermann H (2001) Ectonucleotidases: some developments and a note on nomenclature. Drug Dev Res 52:44–56 Zimmermann H (2006) Ectonucleotidases in nervous system. Purinergic Signal Neuron–Glia Interact 276:113–130 Burnstock G (1978) A basis for distinguishing two types of purinergic receptor. In: Straub RW, Bolis L (eds) Cell membrane receptors for drugs and hormones: a multidisciplinary approach. Raven Press, New York, pp 107–118 Burnstock G (2007) Purine and pyrimidine receptors. Cell Mol Life Sci 64:1471–1483 Ciruela F, Albergaria C, Soriano C et al (2010) Adenosine receptors interacting proteins (ARIPs): behind the biology of adenosine signaling. Biochim Biophys Acta 1798:9–20 Burnstock G (2014) Purinergic signalling: from discovery to current developments. Exp Physiol 99:16–34 Khakh BS, Burnstock G, Kennedy C et al (2001) International Union Of Pharmacology. XXIV. Current status of the nomenclature and properties of P2X receptors and their subunits. Pharmacol Rev 53:107–118 Surprenant A, North RA (2009) Signaling at purinergic P2X receptors. Annu Rev Physiol 71:333–359 Puchalowicz K, Baranowska-Bosiacka I, Dziedziejko V et al (2015) Purinergic signaling and the functioning of the nervous system cells. Cell Mol Biol Lett 20:867–918 Dubyak GR, el-Moatassim C (1993) Signal transduction via P2-purinergic receptors for extracellular ATP and other nucleotides. Am J Physiol 265:C577–C606 Abbracchio MP, Burnstock G, Boeynaems JM et al (2006) International Union of Pharmacology LVIII: update on the P2Y G protein coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol Rev 58:281–341 Oliveira A, Illes P, Ulrich H (2016) Purinergic receptors in embryonic and adult neurogenesis. Neuropharmacology 104:272–281 Beamer E, Gölöncsér F, Horváth G et al (2016) Purinergic mechanisms in neuroinflammation: an update from molecules to behavior. Neuropharmacology 104:94–104 Madeira MH, Boia R, Ambrósio AF et al (2017) Having a coffee break: the impact of caffeine consumption on microglia-mediated inflammation in neurodegenerative diseases. Mediat Inflamm 2017:1–12 Przybyla T, Sakowicz-Burkiewicz M, Pawelczyk T (2018) Purinergic signaling in B cells. Acta Biochim Pol 65:1–7 Allard B, Beavis PA, Darcy PK et al (2016) Immunosuppressive activities of adenosine in cancer. Curr Opin Pharmacol 29:7–16 Vijayan D, Young A, Teng M et al (2017) Targeting immunosuppressive adenosine in cancer. Nat Rev Cancer 17:709–724 Whiteside TL (2017) Targeting adenosine in cancer immunotherapy: a review of recent progress. Expert Rev Anticancer Ther 17:527–535 Kazemi MH, Raoofi Mohseni S, Hojjat-Farsangi M et al (2018) Adenosine and adenosine receptors in the immunopathogenesis and treatment of cancer. J Cell Physiol 233:2032–2057 Burnstock G, Fredholm BB, Verkhratsky A (2011) Adenosine and ATP receptors in the brain. Curr Top Med Chem 11:973–1011 Stockwell J, Jakova E, Cayabyab FS (2017) Adenosine A1 and A2A receptors in the brain: current research and their role in neurodegeneration. Molecules 22:676 Lindberg D, Shan D, Ayers-Ringler J et al (2015) Purinergic signaling and energy homeostasis in psychiatric disorders. Curr Mol Med 15:275–295 Csóka B, Töro G, Vindeirinho J et al (2017) A2A adenosine receptors control pancreatic dysfunction in high-fat-diet-induced obesity. FASEB J 31:4985–4997 Parpura V, Fisher ES, Lechleiter JD et al (2017) Glutamate and ATP at the interface between signaling and metabolism in astroglia: examples from pathology. Neurochem Res 42:19–34 Tozzi M, Novak I (2017) Purinergic receptors in adipose tissue as potential targets in metabolic disorders. Front Pharmacol 8:878 Labazi H, Teng B, Mustafa SJ (2018) Functional changes in vascular reactivity to adenosine receptor activation in type I diabetic mice. Eur J Pharmacol 820:191–197 Ortiz R, Ulrich H, Zarate CA et al (2015) Purinergic system dysfunction in mood disorders: a key target for developing improved therapeutics. Prog Neuropsychopharmacol Biol Psychiatry 57:117–131 Krügel U (2016) Purinergic receptors is psychiatric disorders. Neuropharmacology 104:212–225 Cheffer A, Castillo AR, Corrêa-Velloso JC et al (2017) Purinergic system in psychiatric diseases. Mol Psychiatry 23:94–106 Illes P, Verkhratsky A (2016) Purinergic neurone–glia signalling in cognitive-related pathologies. Neuropharmacology 104:62–75 Burnstock G, Arnett TR, Orriss IR (2013) Purinergic signaling in the musculoskeletal system. Purinergic Signal 9:541–572 Safarzadeh E, Jadidi-Niaragh F, Motallebnezhad M et al (2016) The role of adenosine and adenosine receptors in the immunopathogenesis of multiple sclerosis. Inflamm Res 65:511–520 Pascual O, Casper KB, Kubera C et al (2005) Astrocytic purinergic signaling coordinates synaptic networks. Science 310:113–116 Scemes E, Suadicani SO, Dahl G et al (2007) Connexin and pannexin mediated cell-cell communication. Neuron–Glia Biol 3:199–208 Abbrachio MP, Burnstock G, Verkhratsky A et al (2009) Purinergic signaling in the nervous system: an overview. Trends Neurosci 32:19–29 Lapato AS, Tiwari-Woodruff SK (2017) Connexins and pannexins: at the junction of neuro-glial homeostasis and disease. J Neurosci Res 96:31–44 Vizi ES, Knoll J (1976) The inhibitory effect of adenosine and related nucleotides on the release of acetylcholine. Neuroscience 1:391–398 Dunwiddie TV (1985) The physiological role of adenosine in the central nervous system. Int Rev Neurobiol 27:63–139 Cunha RA, Ribeiro JA (2000) ATP as a presynaptic modulator. Life Sci 68:119–137 Wall MJ, Dale N (2007) Auto-inhibition of rat parallel fibre-Purkinje cell synapses by activity-dependent adenosine release. J Physiol 581:553–565 Fredholm BB, IJzerman AP, Jacobson KA et al (2011) International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors—an update. Pharmacol Rev 63:1–34 Chen JF, Pedata F (2008) Modulation of ischemic brain injury and neuroinflammation by adenosine A2A receptors. Curr Pharm Des 14:1490–1499 Pedata F, Dettori I, Coppi E et al (2016) Purinergic signalling in brain ischemia. Neuropharmacology 104:105–130 Latini S, Pedata F (2001) Adenosine in the central nervous system: release mechanisms and extracellular concentrations. J Neurochem 79:463–484 Augood SJ, Emson PC (1994) Adenosine A2A receptor mRNA is expressed by enkephalin cells but not somatostatin cells in rat striatum: a co-expression study. Mol Brain Res 22:204–210 Dixon AK, Gubitz AK, Sirinathsinghji DJ et al (1996) Tissue distribution of adenosine receptor mRNAs in the rat. Br J Pharmacol 118:1461–1468 Sebastião AM, Ribeiro JA (2009) Adenosine receptors and the central nervous system. Handb Exp Pharmacol 193:471–534 Feoktistov I, Biaggioni I (1997) Adenosine A2B receptors. Pharmacol Rev 49:381–402 Hammarberg C, Schulte G, Fredholm BB (2003) Evidence for functional adenosine A3 receptors in microglia cells. J Neurochem 86:1051–1054 Rivkees SA, Thevananther S, Hao H (2000) Are A3 adenosine receptors expressed in the brain? NeuroReport 11:1025–1030 Burnstock G, Knight GE (2004) Cellular distribution and functions of P2 receptor subtypes in different systems. Int Rev Cytol 240:31–304 Guo W, Xu X, Gao X et al (2008) Expression of P2X5 receptors in the mouse central nervous system. Neuroscience 128:697–712 Amadio S, Montilli C, Picconi B et al (2007) Mapping P2X and P2Y receptor proteins in striatum and substantia nigra: an immunohistological study. Purinergic Signal 3:389–398 Moore D, Chambers J, Waldvogel H et al (2000) Regional and cellular distribution of the P2Y1 purinergic receptor in the human brain: striking neuronal localization. J Comp Neurol 421:374–384 Miras-Portugal MT, Marìn-García P, Carrasquera LM et al (2007) Physiological role of extracellular nucleotides at the central nervous system: signaling through P2X and P2Y receptors. An R Acad Nac Farm 73:1127–1157 Verkhratsky A, Krishtal OA, Burnstock G (2009) Purinoreceptors in neuroglia. Mol Neurobiol 39:190–208 Fukumitsu N, Ishii K, Kimura Y et al (2005) Adenosine A1 receptor mapping of the human brain by PET with 8-dicyclopropylmethyl-1-11C-methyl-3-propylxanthine. J Nucl Med 46:32–37 Ishiwata K, Mishina M, Kimura Y et al (2005) First visualization of adenosine A(2A) receptors in the human brain by positron emission tomography with [11C]TMSX. Synapse 55:133–136 Sheth S, Brito R, Mukherjea D et al (2014) Adenosine receptors: expression, function and regulation. Int J Mol Sci 15:2024–2052 Abbracchio MP, Burnstock G (1998) Purinergic signaling: pathophysiological roles. Jpn J Pharmacol 78:113–145 Fields D, Burnstock G (2006) Purinergic signaling in neuron–glial interactions. Nat Neurosci Rev 7:423–436 Parpura V, Zorec R (2010) Gliotransmission: exocytotic release from astrocytes. Brain Res Rev 63:83–92 Matute C, Cavaliere F (2011) Neuroglial interactions mediated by purinergic signaling in the pathophysiology of CNS disorders. Semin Cell Dev Biol 22:252–259 Verderio C, Matteoli M (2011) ATP in neuron–glia bidirectional signaling. Brain Res Rev 66:106–114 Cunha RA (2016) How does adenosine control neuronal dysfunction and neurodegeneration? J Neurochem 139:1019–1055 Borea PA, Gessi S, Merighi S et al (2017) Pathological overproduction: the bad side of adenosine. Br J Pharmacol 174:1945–1960 Faas MM, Sáez T, de Vos P (2017) Extracellular ATP and adenosine: the Yin and Yang in immune responses? Mol Asp Med 55:9–19 Miras-Portugal MT, Sebastian-Serrano Á, de Diego GarcíaL et al (2017) Neuronal P2X7 receptor: involvement in neuronal physiology and pathology. J Neurosci 37:7063–7072 Burnstock G (2016) An introduction to the roles of purinergic signaling in neurodegeneration, neuroprotection and neuroregeneration. Neuropharmacology 104:4–17 Popat RA, Van Den Eeden SK, Tanner C et al (2011) Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson’s disease. Eur J Neurol 18:756–765 Kumar PM, Paing SS, Li H et al (2015) Differential effect of caffeine intake in subjects with genetic susceptibility to Parkinson’s disease. Sci Rep 5:15492 Yamada-Fowler N, Frekdrikson M, Söderkvist P (2014) Caffeine interaction with glutamate receptor gene GRIN2A: Parkinson’s disease in Swedish population. PLoS ONE 9:e99294 Simon DK, Wu C, Tilley BC et al (2017) Caffeine, creatine, GRIN2A and Parkinson’s disease progression. J Neurol Sci 375:355–359 Liu H, Han X, Li Y et al (2013) Association of P2X7 receptor gene polymorphisms with sporadic Parkinson’s disease in a Han Chinese population. Neurosci Lett 546:42–45 Schiffmann SN, Fisone G, Moresco R et al (2007) Adenosine A2A receptors and basal ganglia physiology. Prog Neurobiol 83:277–292 Fuxe K, Marcellino D, Genedani S et al (2007) Adenosine A(2A) receptors, dopamine D(2) receptors and their interactions in Parkinson’s disease. Mov Disord 22:1990–2017 Olivieira-Giacomelli Á, Naaldijk Y, Sardá-Arroyo L et al (2018) Purinergic receptors in neurological diseases with motor symptoms: targets for therapy. Front Pharmacol 9:325 Fuxe K, Borroto-Escuela DO, Marcellino D et al (2012) GPCR heteromers and their allosteric receptor–receptor interactions. Curr Med Chem 19:356–363 Armentero MT, Pinna A, Ferre S et al (2011) Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson’s disease. Pharmacol Ther 132:280–299 Bogenpohl JW, Ritter SL, Hall RA et al (2012) Adenosine A2A receptor in the monkey basal ganglia: ultrastructural localization and colocalization with the metabotropic glutamate receptor 5 in the striatum. J Comp Neurol 520:570–589 Łukasiewicz S, Blasiak E, Faron-Gorecka A et al (2007) Fluorescence studies of homooligomerization of adenosine A2A and serotonin 5-HT1A receptors reveal the specificity of receptor interactions in the plasma membrane. Pharmacol Rep 59:379–392 Carriba P, Navarro G, Ciruela F et al (2008) Detection of heteromerization of more than two proteins by sequential BRET–FRET. Nat Methods 5:727–733 Navarro G, Carriba P, Gandía J et al (2008) Detection of heteromers formed by cannabinoid CB1, dopamine D2, and adenosine A2A G-protein-coupled receptors by combining bimolecular fluorescence complementation and bioluminescence energy transfer. Sci World J 8:1088–1097 Fuxe K, Ungerstedt U (1974) Action of caffeine and theophyllamine on supersensitive dopamine receptors: considerable enhancement of receptor response to treatment with DOPA and dopamine receptor agonists. Med Biol 52:48–54 Fredholm BB, Fuxe K, Agnati L (1976) Effect of some phosphodiesterase inhibitors on central dopamine mechanisms. Eur J Pharmacol 38:31–38 Kanda T, Jackson MJ, Smith LA et al (2000) Combined use of the adenosine A2A antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp Neurol 162:321–327 Fuzzati-Armentero MT, Cerri S, Levandis G et al (2015) Dual target strategy: combining distinct non-dopaminergic treatments reduces neuronal cell loss and synergistically modulates l-DOPA-induced rotational behavior in a rodent model of Parkinson’s disease. J Neurochem 134:740–747 Canals M, Burgueno J, Marcellino D et al (2004) Homodimerization of adenosine A2A receptors: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J Neurochem 88:726–734 Lee SP, O’Dowd BF, George SR (2003) Homo- and hetero-oligomerization of G protein-coupled receptors. Life Sci 74:173–180 Guo W, Urizar E, Kralikova M et al (2008) Dopamine D2 receptors form higher order oligomers at physiological expression levels. EMBO J 27:2293–2304 Antonelli T, Fuxe K, Agnati L et al (2006) Experimental studies and theoretical aspects on A2A/D2 receptor interactions in a model of Parkinson’s disease. Relevance for l-DOPA induced dyskinesias. J Neurol Sci 248:16–22 Fuxe K, Marcellino D, Borroto-Escuela DO et al (2010) Adenosine-dopamine interactions in the pathophysiology and treatment of CNS disorders. CNS Neurosci Ther 16:e18–e42 Fuxe K, Guidolin D, Agnati LF et al (2015) Dopamine heteroreceptor complexes as therapeutic targets in Parkinson’s disease. Expert Opin Ther Targets 19:377–398 Poewe W, Mahlknecht P, Jankovic J (2012) Emerging therapies for Parkinson’s disease. Curr Opin Neurol 25:448–459 Hauser RA (2011) Future treatments for Parkinson’s disease: surfing the PD pipeline. Int J Neurosci 121(Suppl 2):53–62 Zhu C, Wang G, Li J et al (2014) Adenosine A2A receptor antagonist istradefylline 20 versus 40 mg/day as augmentation for Parkinson’s disease: a meta-analysis. Neurol Res 36:1028–1034 Dungo R, Deeks ED (2013) Istradefylline: first global approval. Drugs 73:875–882 Hauser RA, Stocchi F, Rascol O et al (2015) Preladenant as an adjunctive therapy with levodopa in Parkinson disease: two randomized clinical trials and lessons learned. JAMA Neurol 72:1491–1500 Pinna A (2014) Adenosine A2A receptor antagonists in Parkinson’s disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued. CNS Drugs 28:455–474 Gillespie RJ, Bamford SJ, Botting R et al (2009) Antagonists of the human A(2A) adenosine receptor. 4. Design, synthesis, and preclinical evaluation of 7-aryltriazolol[4,5-d]pyrimidines. J Med Chem 52:33–47 Sitkovsky MV, Hatfield S, Abbott R et al (2014) Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists. Cancer Immunol Res 2:598–605 Hove-Madsen L, Prat-Vidal C, Llach A et al (2006) Adenosine A2A receptors are expressed in human atrial myocytes and modulate spontaneous sarcoplasmic reticulum calcium release. Cardiovasc Res 72:292–302 Llach A, Molina CE, Prat-Vidal C et al (2011) Abnormal calcium handling in atrial fibrillation is linked to up-regulation of adenosine A2A receptors. Eur Heart J 32:721–729 Hauser RA, Olanow CW, Kieburtz KD et al (2014) Tozadenant (SYN115) in patients with Parkinson’s disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurol 13:767–776 LeWitt PA, Guttman M, Tetrud JW et al (2008) Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson’s disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol 63:295–302 Fernandez HH, Greeley DR, Zweig RM et al (2010) Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial. Parkinsonism Relat Disord 16:16–20 Gyoneva S, Shapiro L, Lazo C et al (2014) Adenosine A2A receptor antagonism reverses inflammation-induced impairment of microglial process extension in a model of Parkinson’s disease. Neurobiol Dis 67:191–202 Golembiowska K, Wardas J, Noworyta-Sokolowska K, Kaminska K et al (2013) Effects of adenosine receptor antagonists on the in vivo LPS-induced inflammation model of Parkinson’s disease. Neurotox Res 24:29–40 Villar-Menéndez I, Porta S, Buira SP et al (2014) Increased striatal adenosine A2A receptor levels is an early event in Parkinson’s disease-related pathology and it is potentially regulated by miR-34b. Neurobiol Dis 69:206–214 Hu Q, Ren X, Liu Y et al (2016) Aberrant adenosine A2A receptor signaling contributes to neurodegeneration and cognitive impairments in a mouse model of synucleinopathy. Exp Neurol 283:213–223 Kachroo A, Schwarzschild MA (2012) Adenosine A2A receptor gene disruption protects in an α-synuclein model of Parkinson’s disease. Ann Neurol 71:278–282 Ferreira DG, Batalha VL, Vicente Miranda H et al (2015) Adenosine A2A receptors modulate α-synuclein aggregation and toxicity. Cereb Cortex. https://doi.org/10.1093/cercor/bhv268 Pintor J, Diaz-Rey MA, Miras-Portugal MT (1993) Ap4A and ADP-beta-S binding to P2 purinoreceptors present on rat brain synaptic terminals. Br J Pharmacol 108:1094–1099 Rodriguez-Pascual F, Cortes R, Torres M et al (1997) Distribution of [3H]diadenosine tetraphosphate binding sites in rat brain. Neuroscience 77:247–255 Burnstock G (2008) Purinergic signalling and disorders of the central nervous system. Nat Rev Drug Discov 7:575–590 Heine C, Wegner A, Grosche J et al (2007) P2 receptor expression in the dopaminergic system of the rat brain during development. Neuroscience 149:165–181 Krügel U, Kittner H, Franke H et al (2001) Stimulation of P2 receptors in the ventral tegmental area enhances dopaminergic mechanisms in vivo. Neuropharmacology 40:1084–1093 Krügel U, Kittner H, Illes P (2001) Mechanisms of adenosine 5′-triphosphate-induced dopamine release in the rat nucleus accumbens in vivo. Synapse 39:222–232 Gan M, Moussaud S, Jiang P et al (2015) Extracellular ATP induces intracellular alpha-synuclein accumulation via P2X1 receptor-mediated lysosomal dysfunction. Neurobiol Aging 36:1209–1220 Marcellino D, Suarez-Boomgaard D, Sanchez-Reina MD et al (2010) On the role of P2X7 receptors in dopamine nerve cell degeneration in a rat model of Parkinson’s disease: studies with the P2X7 receptor antagonist A-438079. J Neural Transm 117:681–687 Carmo MR, Menezes AP, Nunes AC et al (2014) The P2X7 receptor antagonist Brilliant Blue G attenuates contralateral rotations in a rat model of Parkinsonism through a combined control of synaptotoxicity, neurotoxicity and gliosis. Neuropharmacology 81:142–152 Hracskó Z, Baranyi M, Csölle C et al (2011) Lack of neuroprotection in the absence of P2X7 receptors in toxin-induced animal models of Parkinson’s disease. Mol Neurodegener 6:28 Wilkaniec A, Gassowska M, Czapski GA et al (2017) P2X7 receptor-pennexin 1 interaction mediates extracellular alpha-synuclein-induced ATP release in neuroblastoma SH-SY5Y cells. Purinergic Signal 13:347–361 Jiang T, Hoekstra J, Heng X et al (2015) P2X7 receptor is critical in α-synuclein-mediated microglial NADPH oxidase activation. Neurobiol Aging 36:2304–2318 Coppi E, Pedata F, Gibb AJ (2012) P2Y1 receptor modulation of Ca2+-activated K+ currents in medium-sized neurons from neonatal rat striatal slices. J Neurophysiol 107:1009–1021 Wang Y, Chang CF, Morales M et al (2013) Diadenosine tetraphosphate protects against injuries induced by ischaemia and 6-hydroxidopamine in rat brain. J Neurosci 23:7958–7965 Yang X, Lou Y, Liu G et al (2017) Microglia P2Y6 receptor is related to Parkinson’s disease through neuroinflammatory process. J Neuroinflamm 14:38 Qian Y, Xu S, Yang X et al (2017) Purinergic receptor P2Y6 contributes to 1-methyl-4-phenylpyridinium-induced oxidative stress and cell death in neuronal SH-SY5Y cells. J Neurosci Res 96:253–264 Neher JJ, Neniskyte U, Hornik T et al (2014) Inhibition of UDP/P2Y6 purinergic signaling prevents phagocytosis of viable neurons by activated microglia in vitro and in vivo. Glia 62:1463–1465 Dunkel P, Chai CL, Sperlágh B et al (2012) Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer’s, Parkinson’s and Huntington’s diseases, and amyotrophic lateral sclerosis. Expert Opin Investig Drugs 21:1267–1308